Adjuvants in cutaneous vaccination: A comprehensive analysis
Journal of Controlled Release · 2024
DOI: 10.1016/j.jconrel.2024.03.045 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Controlled Release, 2024. Verfasst von Mariam Oladejo und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunotherapeutics and Biotechnology, Jerry H Hodge School of Pharmacy, Texas Tech University Health Sciences Center, Abilene, TX 79601…. Hauptthemen laut MEDLINE: Administration, Cutaneous, Vaccination, Adjuvants, Immunologic, Skin. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 217 Literaturangaben.
Abstract (Originalsprache)
Skin is the body's largest organ and serves as a protective barrier from physical, thermal, and mechanical environmental challenges. Alongside, the skin hosts key immune system players, such as the professional antigen-presenting cells (APCs) like the Langerhans cells in the epidermis and circulating macrophages in the blood. Further, the literature supports that the APCs can be activated by antigen or vaccine delivery via multiple routes of administration through the skin. Once activated, the stimulated APCs drain to the associated lymph nodes and gain access to the lymphatic system. This further allows the APCs to engage with the adaptive immune system and activate cellular and humoral immune responses. Thus, vaccine delivery via skin offers advantages such as reliable antigen delivery, superior immunogenicity, and convenient delivery. Several preclinical and clinical studies have demonstrated the significance of vaccine delivery using various routes of administration via skin. However, such vaccines often employ adjuvant/(s), along with the antigen of interest. Adjuvants augment the immune response to a vaccine antigen and improve the therapeutic efficacy. Due to these reasons, adjuvants have been successfully used with infectious disease vaccines, cancer immunotherapy, and immune-mediated diseases. To capture these developments, this review will summarize preclinical and clinical study results of vaccine delivery via skin in the presence of adjuvants. A focused discussion regarding the FDA-approved adjuvants will address the experiences of using such adjuvant-containing vaccines. In addition, the challenges and regulatory concerns with these adjuvants will be discussed. Finally, the review will share the prospects of adjuvant-containing vaccines delivered via skin.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Immunotherapeutics and Biotechnology, Jerry H Hodge School of Pharmacy, Texas Tech University Health Sciences Center, Abilene, TX 79601, USA.
- Department of Pharmaceutical Sciences, Bill Gatton College of Pharmacy, East Tennessee State University, Johnson City, TN, USA.
- Department of Pharmaceutical Sciences, Bill Gatton College of Pharmacy, East Tennessee State University, Johnson City, TN, USA. Electronic address: puria1@etsu.edu.
- Wegmans School of Pharmacy, St. John Fisher University, 3690 East Ave, Rochester, NY 14618, USA. Electronic address: lchablani@sjf.edu.
Zitieren
APA
Oladejo, M., Tijani, A. O., Puri, A., & Chablani, L. (2024). Adjuvants in cutaneous vaccination: A comprehensive analysis. Journal of Controlled Release. https://doi.org/10.1016/j.jconrel.2024.03.045
Vancouver
Oladejo M, Tijani AO, Puri A, Chablani L. Adjuvants in cutaneous vaccination: A comprehensive analysis. Journal of Controlled Release. 2024. doi:10.1016/j.jconrel.2024.03.045
BibTeX
@article{Oladejo2024,
author = {Oladejo, Mariam and Tijani, Akeemat O and Puri, Ashana and Chablani, Lipika},
title = {Adjuvants in cutaneous vaccination: A comprehensive analysis},
journal = {Journal of Controlled Release},
year = {2024},
doi = {10.1016/j.jconrel.2024.03.045}
}
EUVIMED